Erasca, Inc. 2023 Q3 Form 10-Q Summary
Business context and reporting period
Erasca is a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers. The filing covers the unaudited quarter and nine months ended September 30, 2023, compared with the corresponding 2022 periods. The company has no approved products, has generated no product revenue, and expects product revenue only if and when candidates receive regulatory approval.
Key financial metrics
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $25.2 million, versus $28.2 million | $79.0 million, versus $83.1 million |
| General and administrative expense | $9.4 million, versus $8.8 million | $28.6 million, versus $24.3 million |
| Total operating expenses | $34.7 million, versus $37.0 million | $107.7 million, versus $109.4 million |
| Net loss | $30.4 million, versus $35.5 million | $95.3 million, versus $107.6 million |
| Net loss per share | $0.20, versus $0.29 | $0.64, versus $0.90 |
| Interest income | $4.3 million, versus $1.5 million | $12.5 million, versus $2.0 million |
| Operating cash flow | Not separately provided for the quarter | $(76.4) million, versus $(76.9) million |
Margins are not meaningful because the company has no revenue. Stock-based compensation was $6.2 million in the third quarter and $20.1 million for the first nine months. The company reported no debt financing; liabilities primarily consisted of operating lease liabilities of $56.8 million, including $3.8 million current and $52.9 million long-term.
At September 30, 2023, cash and cash equivalents were $112.9 million, short-term marketable securities were $183.8 million, and long-term marketable securities were $46.9 million. Total cash, cash equivalents, and marketable securities were approximately $343.6 million. Total assets were $419.4 million, total liabilities were $80.4 million, and stockholders’ equity was $339.0 million. The accumulated deficit was $576.3 million.
Material changes versus the prior comparable period
- Third-quarter net loss improved by $5.1 million, and nine-month net loss improved by $12.2 million, primarily because of lower operating expenses and higher interest income.
- Research and development expense declined $3.0 million in the quarter and $4.1 million year to date, largely reflecting pipeline prioritization and lower clinical, preclinical, discovery, outsourced-service, and consulting costs.
- General and administrative expense increased $0.7 million in the quarter and $4.4 million year to date because of higher personnel costs, headcount, facilities costs, and stock-based compensation.
- Interest income increased materially because of higher cash and marketable-securities balances and prevailing interest rates.
- Investing cash outflows increased to $95.8 million from $66.2 million, primarily due to purchases of marketable securities and $20.0 million of in-process research and development payments related to the 2022 Novartis license transaction.
- Shares outstanding increased to approximately 150.5 million at September 30, 2023 from approximately 149.3 million at December 31, 2022; weighted-average shares increased to 150.0 million from 120.2 million year over year.
Guidance, outlook, commentary, risks, and unusual items
- Management expects existing cash, cash equivalents, and marketable securities to fund operations into the second half of 2025, although actual cash usage may differ materially from this estimate.
- The company plans to begin a pivotal Phase 3 trial of naporafenib plus trametinib in NRAS-mutated melanoma in the first half of 2024. A Phase 1b naporafenib trial in RAS Q61X solid tumors began in August 2023.
- Management expects a HERKULES-3 ERAS-007 combination dose-expansion data readout between the second half of 2023 and the first half of 2024, and an ERAS-601 combination data readout in the first half of 2024.
- The company deprioritized several programs or indications based on clinical data, including ERAS-007 combinations with osimertinib, palbociclib, and ERAS-601 in specified settings. ERAS-3490 was also deprioritized before enrolling patients because of competition in the KRAS G12C inhibitor market.
- The company was informed that an investigator-sponsored KRAS G12C inhibitor combination trial would not proceed. The UCSF license agreement was terminated effective October 6, 2023.
- Potential future obligations include up to $80.0 million of Novartis regulatory milestones and up to $200.0 million of sales milestones, plus low-single-digit royalties. Other license agreements also contain milestone and royalty obligations; no contingent milestones were accrued because they were not probable or estimable.
- Future minimum operating lease payments totaled $82.7 million as of September 30, 2023, including $44.4 million due thereafter.
- The company expects operating expenses and losses to increase as clinical development advances and states that additional capital will likely be required. Potential funding sources include equity offerings, debt, collaborations, licenses, or other strategic arrangements.
- Risks include clinical and regulatory failure, enrollment and trial-cost uncertainty, manufacturing and supply-chain dependence, competition, intellectual-property matters, dilution or unfavorable financing terms, and potential inability to raise capital.
- No material legal proceedings or material changes to previously disclosed risk factors were reported. Management concluded that disclosure controls and procedures were effective as of September 30, 2023.
Important facts for investors to verify
- Confirm the timing, design, enrollment, and funding requirements for the planned Phase 3 naporafenib trial and other 2024 clinical milestones.
- Monitor cash burn relative to the stated runway into the second half of 2025, including the impact of expanded trials, licensing payments, and lease commitments.
- Assess clinical efficacy and safety data supporting naporafenib, ERAS-007, ERAS-601, and ERAS-801, particularly after the disclosed program deprioritizations.
- Review the potential dilution and financing implications of the $200 million at-the-market facility, under which no shares had been sold as of September 30, 2023.
- Track contingent milestone, royalty, and sublicensing obligations under the Novartis and other license agreements.
- Reconcile reported liquidity measures: approximately $296.7 million of cash, cash equivalents, and short-term securities versus approximately $343.6 million when long-term marketable securities are included.